Smith, F. O., Goff, S. L., Klapper, J. A., Levy, C., Allen, T., Mavroukakis, S. A., & Rosenberg, S. A. (2007). Risk of bowel perforation in patients receiving interleukin-2 after therapy with anti-CTLA 4 monoclonal antibody. J Immunother, 30(1), 130. https://doi.org/10.1097/01.cji.0000211334.06762.89

Smith, Franz O., Stephanie L. Goff, Jacob A. Klapper, Catherine Levy, Tamika Allen, Sharon A. Mavroukakis, and Steven A. Rosenberg. “Risk of bowel perforation in patients receiving interleukin-2 after therapy with anti-CTLA 4 monoclonal antibody.” J Immunother 30, no. 1 (January 2007): 130. https://doi.org/10.1097/01.cji.0000211334.06762.89.

Smith FO, Goff SL, Klapper JA, Levy C, Allen T, Mavroukakis SA, et al. Risk of bowel perforation in patients receiving interleukin-2 after therapy with anti-CTLA 4 monoclonal antibody. J Immunother. 2007 Jan;30(1):130.

Smith, Franz O., et al. “Risk of bowel perforation in patients receiving interleukin-2 after therapy with anti-CTLA 4 monoclonal antibody.” J Immunother, vol. 30, no. 1, Jan. 2007, p. 130. Pubmed, doi:10.1097/01.cji.0000211334.06762.89.

Smith FO, Goff SL, Klapper JA, Levy C, Allen T, Mavroukakis SA, Rosenberg SA. Risk of bowel perforation in patients receiving interleukin-2 after therapy with anti-CTLA 4 monoclonal antibody. J Immunother. 2007 Jan;30(1):130.